News Releases

Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community...

The Quest Diagnostics Foundation continues support of the American Heart Association’s Scholars programs with renewed investment to increase diversity in health care workforce and expand...

Foundation grant will help NYC-based nonprofit expand reach of its innovative curriculum to 50 schools in Baltimore and Houston Funding will also support film screening tour of award-winning...

Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6%...

Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J., Dec. 19, 2023 /PRNewswire/ -- Quest...

Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C SECAUCUS, N.J., Dec....

Third quarter revenues of $2.30 billion, down 7.7% from 2022 Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9%...

Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5%...

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer SECAUCUS, N.J. and MELBOURNE, Australia, July 13, 2023 /

June 2023 For more information or to schedule an interview with one of our medical experts, please email mediacontact@questdiagnostics.com. Breaking Science News: Only one in three adults (34%)...

Beginning February 2023, Quest Diagnostics plans to discontinue providing a monthly COVID-19 media statement, including monthly COVID-19 volume and turnaround time figures. Instead, this media...

First quarter revenues of $2.33 billion, down 10.7% from 2022 First quarter reported diluted earnings per share ("EPS") of $1.78, down 39.0% from 2022; and adjusted diluted EPS of $2.04, down...

New Panels Aimed at the Millions of Americans Still Suffering From COVID-19 Side Effects SECAUCUS, N.J., March 21, 2023 /PRNewswire/ -- The consumer-initiated testing business from the leader in...

Updates 2023-26 compound annual growth rate (CAGR): Revenues expected to grow at mid single-digit rate; adjusted diluted earnings per share (EPS)* expected to grow at high single-digit rate...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Tower Health, a regional integrated healthcare system in Pennsylvania, are teaming up to enhance...

Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021; and adjusted diluted EPS of $1.98, down...

Quest Launches the First Annual "Know Your Health" Survey to Inspire Americans to Take Control of Their Well-being in 2023 SECAUCUS, N.J., Jan. 23, 2023 /PRNewswire/ -- The consumer-initiated...

Marks 1-Year since Quest Diagnostics Announced Plans to Acquire Pack Health to Extend Digital Engagement and Coaching Services to Health Plans, Employers and Life Sciences Companies BIRMINGHAM, Ala.,

Our Media Statement about COVID-19 Testing This is an evolving situation. Please check back to this page periodically for the latest information For more information, members of the media may...

Analysis of 20 million clinical drug tests performed by Quest Diagnostics over the past decade shows increases in drug mixing and amphetamines use, and highlights the need for drug misuse...

Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, has been awarded a group purchasing agreement for its laboratory stewardship solution with Premier...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Jim Davis has succeeded Steve Rusckowski as the CEO and President of Quest...

Third quarter revenues of $2.49 billion, down 10.4% from 2021 Third quarter reported diluted earnings per share ("EPS") of $2.17, down 46.0% from 2021; and adjusted diluted EPS of $2.36, down...